Cell Viability Assays Market – By Product (Consumables [Assay Kits {Tetrazolium Reduction, Resazurin Cell Viability Assay Kits}, Reagents, Microplates], Instruments [Spectrophotometers, Flow Cytometers]), Application, End-User – Global Forecast 2024 – 2032

Cell Viability Assays Market Size

Cell Viability Assays Market size was valued at USD 1.7 billion in 2023 and is poised to grow at 8.5% CAGR from 2024 and 2032. Advances in biotechnology and the increasing adoption of precision medicine have fueled the demand for precise and reliable cell viability testing. Additionally, the rising prevalence of chronic diseases, such as cancer and cardiovascular disorders, necessitates the development of novel therapeutics and efficient drug discovery processes, which rely heavily on cell viability assays.
 

Furthermore, the growing emphasis on early-stage drug testing, coupled with a surge in clinical trials aimed at evaluating new therapies, further boosts market growth. Expanding research activities in cellular and molecular biology, along with increased funding for research and development, contribute to the sustained growth of the market. The adoption of advanced technologies, such as high-throughput screening and automated assays, enhances the efficiency and accuracy of cell viability testing, contributing to the market's expansion.
 

Cell viability assays are experimental techniques used to assess the ability of cells to survive and function over a given period under specific conditions. These assays are essential in cell biology, toxicology, drug development, and various biomedical research fields to determine the effects of treatments, chemicals, or environmental changes on cell health. They are particularly vital in drug discovery for evaluating the cytotoxicity of compounds, in cancer research for assessing the effectiveness of therapies, and in many other applications where cell health is a critical factor.
 

Cell Viability Assays Market Trends

• As researchers and clinicians explore the potential of stem cells for regenerative medicine, drug discovery, and disease modeling, there is a growing need for reliable and accurate cell viability assays.
   
• These assays are essential for assessing the health, proliferation, and functionality of stem cells, which are critical for evaluating therapeutic outcomes and optimizing treatment protocols.
   
• Additionally, the expansion of stem cell research not only fuels demand for advanced assay technologies but also drives innovation in assay development, contributing to the overall growth of the market.
   
• Enhanced assay capabilities enable researchers to gain more precise and actionable insights, accelerating progress in stem cell applications and ultimately advancing the field of regenerative medicine.
   
• Thus, as stem cell research advances and its applications expand, the demand for accurate and reliable cell viability assays continues to rise, further driving overall market growth.
   

Cell Viability Assays Market Analysis

Based on product, the market is classified into consumables and instruments. The consumables segment dominated the market with 62.4% of market share in 2023. The consumables segment is further sub-classified into assay kits, reagents, and microplates.
 

• The consumables segment holds the highest market share in the market primarily due to their frequent use and wide range of applications. Consumables such as reagents, assay kits, and cell culture media are essential for routine research and testing, necessitating regular replenishment.
   
• Consumables cater to a wide range of applications within cell viability assays, including various types of assays such as tetrazolium reduction assays, resazurin assays, and dye exclusion assays.
   
• The diversity of applications and the need for specific consumables for different types of assays contribute to the high market share of this segment.
   

Based on application, the cell viability assays market is segmented into stem cell research, drug discovery & development, basic research, clinical & diagnostic applications, and other applications. The stem cell research segment in 2023 was valued at USD 713.3 million in 2023.
 

• Stem cell research is at the forefront of regenerative medicine and therapeutic development, driving substantial demand for cell viability assays. The growing focus on stem cell-based treatments for various diseases drives demand for reliable cell viability assays, which are essential for evaluating stem cell health, differentiation, and therapeutic potential.
   
• The complexity and specificity of stem cell studies necessitate detailed analysis, further increasing the need for specialized assays.
   
• Additionally, the broad applications of stem cells in disease modeling, drug screening, and personalized medicine contribute to the segment's prominence.
   

Based on end-user, the cell viability assays market is bifurcated into biopharmaceutical & pharmaceutical companies, CROs & CMOs, academic & research institutes, and diagnostic laboratories. The biopharmaceutical & pharmaceutical companies’ segment is expected to grow at 8.6% during the analysis timeframe.
 

• Biopharmaceutical and pharmaceutical companies are heavily involved in the drug development process, which relies on cell viability assays to evaluate the efficacy and safety of new drug candidates, thereby driving the growth of this segment.
   
• Stringent regulatory requirements also contribute to the segment's dominance as these agencies require thorough testing, including cell viability assays, to ensure that new pharmaceuticals meet safety and efficacy standards before approval.
   
• Additionally, substantial investments in research and development by these companies fuel the market for cell viability assays.
   

North America cell viability assays market accounted for USD 696 million and is expected to grow lucratively at 8.3% CAGR.
 

• The region boasts numerous prestigious research and academic institutions that are at the forefront of scientific and medical research which frequently utilize cell viability assays in their studies related to drug discovery, cancer research, and stem cell research.
   
• The high level of research activity and investment in these institutions’ fuels demand for advanced cell viability assays and supports ongoing market growth.
   

The U.S. cell viability assays market accounted for USD 641 million in 2023 and is expected to reach USD 1.3 billion by 2032.
 

• The U.S. market benefits significantly from its advanced technological capabilities and supportive regulatory framework. The country leads in adopting cutting-edge technologies like high-throughput screening and automated systems, which enhance the accuracy and efficiency of cell viability testing.
   
• Additionally, favourable regulatory environment in the U.S. provides clear guidelines and requirements for drug approval processes, including the need for comprehensive cell viability data. Agencies like the FDA ensure that cell viability assays are integral to meeting regulatory standards for drug safety and efficacy, further boosting the market's growth.
   

China cell viability assays market is predicted to showcase remarkable growth over the forecast period.
 

• The country's rapid expansion in the pharmaceutical and biotechnology sectors, coupled with increased investments in research and development, drives the demand for advanced cell viability assays.
   
• China’s growing focus on drug discovery, cancer research, and personalized medicine fuels the need for precise and reliable assays.
   
• The combination of a booming life sciences sector, significant R&D investments, and favorable regulatory conditions positions China for substantial growth in the market.
   

India is expected to witness significant growth in global cell viability assays market.
 

• The country's expanding research and development sector, driven by increased investments in biotechnology and pharmaceuticals, is creating a rising demand for advanced cell viability assays.
   
• Additionally, the growing prevalence of chronic diseases and cancer is fueling the need for accurate and reliable assays to assess cell health and drug efficacy.
   
• India’s strong focus on improving healthcare infrastructure and fostering innovation through public and private partnerships further enhances the market's growth potential.
   
• Thus, as Indian research institutions and pharmaceutical companies increasingly adopt cutting-edge technologies, the market is poised for robust expansion in the country.
   

Cell Viability Assays Market Share

The cell viability assays industry is characterized by a highly competitive landscape, with key players vying for market share through innovation and strategic initiatives. Companies are focusing on integrating advanced technologies such as high-throughput screening, automation, and real-time monitoring to enhance assay accuracy and efficiency. Collaborations, acquisitions, and partnerships are common strategies used to expand market presence and access new technologies.
 

Cell Viability Assays Market Companies

Prominent players operating in the cell viability assays industry include:

• Abcam plc
• Abnova Corporation
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• BioTek Instruments, Inc. (Agilent Technologies, Inc.)
• Biotium, Inc.
• Canvax Biotech S.L.
• Creative Bioarray, Inc.
• Danaher Corporation
• Geno Technology, Inc.
• GE Healthcare Technologies, Inc.
• Merck KGaA
• PerkinElmer, Inc.
• Promega Corporation
• Thermo Fisher Scientific Inc.
   

The cell viability assays market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Consumables
  • Assay kits
    • Tetrazolium reduction assay kits
      • MTT assays
      • MTS assays
      • XTT assays
      • Other tetrazolium reduction assay kits
    • Resazurin cell viability assay kits
    • Calcein-AM cell viability assay kits
    • Other assay kits
  • Reagents
  • Microplates
• Instruments
  • Spectrophotometers
  • Flow cytometers
  • Automated cell counters
  • Microscopy
  • Cell imaging & analysis systems

Market, By Application

• Stem cell research
• Drug discovery & development
• Basic research
• Clinical & diagnostic applications
• Other applications

Market, By End-user

• Biopharmaceutical & pharmaceutical companies
• CROs & CMOs
• Academic & research institutes
• Diagnostic laboratories

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa